A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
NCT ID: NCT01833494
Last Updated: 2018-10-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
161 participants
INTERVENTIONAL
2013-03-18
2014-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
NCT01521494
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
NCT01850602
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
NCT01850641
A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
NCT01852682
Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
NCT03864458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PA21
PA21
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PA21
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dialysis patients with hyperphosphatemia
Exclusion Criteria
* Patients having severe gastrointestinal disorders.
* Patients having severe hepatic disorders.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kissei Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
JAPAN
Multiple Locations, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA1302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.